Literature DB >> 19808699

Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.

Kevin J Freise1, John A Widness, Peter Veng-Pedersen.   

Abstract

Despite the common occurrence of anemia in very low birth weight (VLBW) infants, the erythropoiesis and Hb production rates and their relationship to plasma erythropoietin (EPO) concentrations remain unknown in these subjects. To determine these quantities, all blood removed by phlebotomy and administered by red blood cell (RBC) transfusion over the first 30 days of life was recorded in 14 ventilated VLBW infants born at 24 to 28 weeks of gestation. Discarded blood from frequent clinically ordered laboratory blood samples was used to construct plasma EPO, Hb, and RBC concentration-time profiles for each infant. A pharmacodynamic Hb mass balance model that accounted for the dynamic hematological conditions experienced by these infants was simultaneously fitted to the plasma EPO, Hb, and RBC concentrations from each individual subject, while accounting for subject growth. Based on the model estimates, an average of 4.69 g of Hb was produced over the first 30 days of life, compared with 5.97 g removed by phlebotomies and 12.3 g administered by transfusions. These high transfusion amounts were consistent with a relatively short RBC life span and rapidly expanding blood volume with infant growth. The estimated mean body weight-scaled Hb production rate dropped nearly 3-fold after birth to 0.144 g/day x (kg)(3/4). Although only estimated in a subset of the subjects, the mean plasma EPO EC(50) of 28.5 mU/ml and maximal Hb production rate (E(max)) indicated that a severalfold increase in Hb production rate could be achieved with only a modest increase in plasma EPO concentrations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808699      PMCID: PMC2802482          DOI: 10.1124/jpet.109.159905

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

Review 1.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Authors:  Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-25       Impact factor: 2.745

3.  How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity.

Authors:  Ronald G Strauss
Journal:  Transfusion       Date:  2008-01-07       Impact factor: 3.157

Review 4.  Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.

Authors:  A Ohlsson; S M Aher
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

5.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

Authors:  Wojciech Krzyzanski; William J Jusko; Mary C Wacholtz; Neil Minton; Wing K Cheung
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

6.  The effect of anticoagulant, storage temperature and dilution on cord blood hematology parameters over time.

Authors:  K J Freise; R L Schmidt; E L Gingerich; P Veng-Pedersen; J A Widness
Journal:  Int J Lab Hematol       Date:  2008-04-14       Impact factor: 2.877

7.  Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods.

Authors:  Marleen Luten; Bregt Roerdinkholder-Stoelwinder; Nicolaas P M Schaap; Willem J de Grip; Harry J Bos; Giel J C G M Bosman
Journal:  Transfusion       Date:  2008-05-13       Impact factor: 3.157

8.  Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

9.  Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-14       Impact factor: 2.745

Review 10.  Mechanistic basis of using body size and maturation to predict clearance in humans.

Authors:  Brian J Anderson; Nick H G Holford
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

View more
  25 in total

1.  Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates.

Authors:  Mudit Kulshrestha; Martha Sola-Visner; John A Widness; Peter Veng-Pedersen; Donald E Mager
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-10-31       Impact factor: 4.733

2.  Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cell-biotin dose.

Authors:  Robert L Schmidt; Donald M Mock; Robert S Franco; Robert M Cohen; Anne K North; José A Cancelas; Christof Geisen; Ronald G Strauss; Alexander P Vlaar; Demet Nalbant; John A Widness
Journal:  Transfusion       Date:  2017-03-05       Impact factor: 3.157

Review 3.  Nonpharmacological, blood conservation techniques for preventing neonatal anemia--effective and promising strategies for reducing transfusion.

Authors:  Patrick D Carroll; John A Widness
Journal:  Semin Perinatol       Date:  2012-08       Impact factor: 3.300

4.  Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates?

Authors:  E Henry; R D Christensen; M J Sheffield; L D Eggert; P D Carroll; S D Minton; D K Lambert; S J Ilstrup
Journal:  J Perinatol       Date:  2014-09-25       Impact factor: 2.521

Review 5.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

6.  Jack Widness: the importance of connections.

Authors:  Steven J McElroy
Journal:  Pediatr Res       Date:  2018-01-10       Impact factor: 3.756

7.  Multidose optimization simulation of erythropoietin treatment in preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

8.  A mathematical modeling approach to quantify the role of phlebotomy losses and need for transfusions in neonatal anemia.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Peter Veng-Pedersen
Journal:  Transfusion       Date:  2012-10-04       Impact factor: 3.157

9.  Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Gretchen Cress; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2013-11-11       Impact factor: 3.756

10.  Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Authors:  Mohammad I Saleh; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.